Depiction of Being patient: what delays access to new drugs in Europe?

Being patient: what delays access to new drugs in Europe?



On average, the first citizen to access a new drug in Belgium will wait 13 months longer for it than someone prescribed the same drug in Germany or the UK, despite an EU-wide licensing process. This suggests that country-specific drug regulation—the ‘fourth hurdle’ faced by drug manufacturers—may go a long way to explaining launch delay across Europe.


Related

Articles
3 minute read
Depiction of The future funding of the England & Wales water sector: Ofwat’s draft determinations

The future funding of the England & Wales water sector: Ofwat’s draft determinations

On Thursday 11 July, Ofwat (the England and Wales water regulator) published its much anticipated Draft Determinations (DDs). As part of the PR24 price review, this sets out its provisional assessment of allowed revenues and performance targets for AMP8 (2025–30)—and will be of great interest to water companies, investors,… Read More

< 1 minute read
Depiction of Deceptive patterns: how can we make choices fairer online?

Deceptive patterns: how can we make choices fairer online?

Online, every click and swipe is subtly influenced by how choices are presented to you. In a world where what we watch, listen to, read, and buy is the result of responding to the choices presented to us on a screen, this choice architecture is hugely important. We may not… Read More

Back to top